Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions

• Main Authors: Helena Leonie Hanae Loer (Author), Denise Türk (Author), José David Gómez-Mantilla (Author), Dominik Selzer (Author), Thorsten Lehr (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The antiplatelet agent clopidogrel is listed by the FDA as a strong clinical index inhibitor of cytochrome P450 (CYP) 2C8 and weak clinical inhibitor of CYP2B6. Moreover, clopidogrel is a substrate of-among others-CYP2C19 and CYP3A4. This work presents the development of a whole-body physiologically...